Czechia· CZ-0290109
KEYTRUDA
A pembrolizumab product containing pembrolizumab, registered in Czechia by Merck Sharp & Dohme B.V., Haarlem. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Pembrolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FF02 (pembrolizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Pembrolizumab · ATC L01FF02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pembrolizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pembrolizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$245.95
The record
At a glance
SÚKL (Czech Republic)- Active substance
- PEMBROLIZUMAB
- Manufacturer
- Merck Sharp & Dohme B.V., Haarlem
- Country
- Czechia (CZ)
- ATC code
- L01FF02
- ATC class
- Pembrolizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for pembrolizumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pembrolizumab · interactions on record
20 records
- 3 severe
- 17 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pembrolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKeytruda 395 mgMerck Sharp & Dohme
- IcelandKEYTRUDAMerck Sharp & Dohme B.V.*
- NorwayKeytrudaMerck Sharp & Dohme B.V
- PolandKeytrudaMerck Sharp & Dohme B.V.
- SwedenKEYTRUDA 395 mg Injektionsvätska, lösningMerck Sharp & Dohme BV
- United KingdomKeytruda 100mg/4ml concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- SpainKEYTRUDA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandKeytrudaParanova Oy
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Keytruda
- Liechtenstein · Keytruda
- Norway · Keytruda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/052bb355-8cd0-4c5b-b8f0-2245e1d0afb0 GET /v1/drugs/052bb355-8cd0-4c5b-b8f0-2245e1d0afb0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL",
"source": "sukl",
"strength": "395MG",
"pack_size": "1X2,4ML",
"substance": "PEMBROLIZUMAB",
"cz_kod_sukl": "0290109",
"product_type": "BT",
"substance_codes": "20195",
"registration_state": "R",
"registration_number": "EU/1/15/1024/004"
}See everything about pembrolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.